Key facts
- It has raised $2.7M; the latest was Seed Round ($2.1M) in Oct 2025.
- Notable investors include Techstars, Enterprise Ireland, NDRC, MassBio, Fernando Ferrer — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Meta-Flux
- ·The full record, as it builds
Funding rounds
No funding rounds for Meta-Flux are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Meta-Flux
Developer of an artificial intelligence-assisted diagnostics platform intended for personalized medicine and disease prevention. The company's platform minimizes the time it takes to analyze patterns and fluctuations seen in customized medicine to offer systems biology for swift diagnostic and prognostic tools, combines proprietary omics data with auto-ingested public sources to create bespoke knowledge graphs and in silico cell lines, tissues and patient cohorts and provides adaptive experimentation through multi-omic data, enabling the healthcare industry to identify the onset of disease years in advance accurately predicting the risk.
- Sector
- Healthcare
- HQ
- Dublin, Ireland
- Founded
- 2021
- Employees
- 4
- Website
- meta-flux.com/
- Ownership
- Privately Held (backing)
Meta-Flux doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Meta-Flux shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Meta-Flux in its N-PORT filings yet. We sweep new filings monthly.